Get the Stockscreener App
1.56
20.41%
-0.40
Neumora Therapeutics Inc stock is traded at $1.56, with a volume of 2.11M.
It is down -20.41% in the last 24 hours and up +95.91% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.96
Open:
$1.88
24h Volume:
2.11M
Relative Volume:
1.48
Market Cap:
$252.33M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.6155
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-33.62%
1M Performance:
+95.91%
6M Performance:
-19.17%
1Y Performance:
-87.65%
1-Day Range:
$1.515
$1.92
1-Week Range:
$1.515
$2.3992
52-Week Range:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.56 | 317.03M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
How strong is Neumora Therapeutics Inc. company’s balance sheetExpert Picks Entry Points For 2025 - jammulinksnews.com
Neumora Therapeutics (NMRA) Expected to Post Earnings on Wednesday - MarketBeat
What is the dividend policy of Neumora Therapeutics Inc. stockPost Market Planner That Work - jammulinksnews.com
Why is Neumora Therapeutics Inc. stock attracting strong analyst attentionWealth Building Planner With Proven Results - jammulinksnews.com
What are analysts’ price targets for Neumora Therapeutics Inc. in the next 12 monthsAI Powered Tracker With Low Risk - jammulinksnews.com
How many analysts rate Neumora Therapeutics Inc. as a “Buy”Value Investing Tips For Fast Growth - jammulinksnews.com
What are the technical indicators suggesting about Neumora Therapeutics Inc.Chart Pattern Guidance To Watch Now - jammulinksnews.com
How does Neumora Therapeutics Inc. generate profit in a changing economyFinancial News Report For Fast Growth - jammulinksnews.com
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionStrong Buy With Technical Confidence Supported - beatles.ru
Published on: 2025-07-30 12:15:41 - metal.it
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating - Insider Monkey
Published on: 2025-07-29 01:24:00 - metal.it
What is Neumora Therapeutics Inc. company’s growth strategyNavigate market volatility with smart strategies - jammulinksnews.com
What institutional investors are buying Neumora Therapeutics Inc. stockBreakout Stocks Tips That Work - jammulinksnews.com
How volatile is Neumora Therapeutics Inc. stock compared to the marketRecord-setting profit potential - jammulinksnews.com
When is Neumora Therapeutics Inc. stock expected to show significant growthCapitalize on market trends with expert guidance - jammulinksnews.com
Is it the right time to buy Neumora Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com
Is Neumora Therapeutics Inc. a good long term investmentFree Investment Community - PrintWeekIndia
Neumora Therapeutics Inc. Stock Analysis and ForecastExponential wealth increase - PrintWeekIndia
What drives Neumora Therapeutics Inc. stock priceHigh-yield growth strategies - PrintWeekIndia
Is Neumora Therapeutics Inc. stock overhyped or has real potentialExceptional portfolio growth - jammulinksnews.com
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) PT at $7.14 - MarketBeat
Neumora Soared 24.33%—What Sparked This Volcanic Rally in a Biotech Underdog? - AInvest
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - The Manila Times
What analysts say about Neumora Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating - MSN
What makes Neumora Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):